Recent advances in management of acute myeloid leukemia (AML)

Indian Journal of Pediatrics

Volumn 75, Issue 8, 2008, Pages 831-837

  Shah, Manasi ^b,c   Agarwal, Bharat ^a  

^a B J WADIA HOSPITAL FOR CHILDREN   (India)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Acute myeloid leukemia (AML); FLT3 inhibitors; Gemtuzumab ozogamicin; Oncogenes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD33 ANTIGEN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IDARUBICINOL; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SU 5614; SUNITINIB; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; BLAST CELL; BONE MARROW SUPPRESSION; BONE PAIN; CANCER REGRESSION; CARDIOTOXICITY; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RETENTION; DYSGEUSIA; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENETIC DAMAGE; GINGIVITIS; HEADACHE; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; HYPOXIA; INJECTION SITE REACTION; LEG EDEMA; LIVER TOXICITY; LUNG TOXICITY; MINIMAL RESIDUAL DISEASE; MOUTH ULCER; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; PATHOGENESIS; REMISSION; SEPSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION;

EID: 51349092514     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12098-008-0155-x     Document Type: Conference Paper

References (43)

1. T. Chowdhury J.M. Brady 2008 Insights from clinical studies into the role of MLL gene in infant and childhood leukemia Blood Cell, Molecules Diseases 40 192 199
2. Y. Ravindranath 2003 Recent advances in pediatric acute lymphoblastic and myeloid leukemia Curr Opin Oncol 15 23 25
3. G.J. Kaspers U. Creutzig 2005 Pediatric acute myeloid leukemia: international progress and future directions Leukemia 19 2025 2029
4. J. W. Vardiman N. L. Harris R. D. Brunning 2002 World Health Organization (WHO) classification of myeloid neoplasms Blood 100 2292 2302
5. G.J.L. Kaspers Z. CM 2007 Pediatric acute myeloid leukemia: towards high-quality cure of all patients Hematologica 92 1519 1532
6. J.E. Rubnitz B. Gibson F.O. Smith 2008 Acute myeloid leukemia Pediatr Clin North Am 55 21 51
7. C.D. Bloomfield D. Lawrence J.C. Byrd A. Carroll M.J. Pettenati R. Tantravahi 1998 Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 4173 4179
8. G. David W. Helen O. Fiona W. Keith H. Christine H. Georgina 1998 Goldstone on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial Blood 92 2322 2333
9. S. Meshinchi T.A. Alonzo D.L. Stirewalt M. Zwaan M. Zimmerman D. Reinhardt 2006 Clinical implications of FLT3 mutations in pediatric AML Blood 108 3654 3661
10. P. Brown E. McIntyre S. Meshinchi N. Lacayo G. Dahl 2007 The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood 110 979 985
11. U. Creutzig J. Ritter H. Riehm M. Budde G. Schellong 1987 The childhood AML studies BFM-78 and-83: treatment results and risk factor analysis Haematol Blood Transfus 30 71 75
12. R.F. Stevens I.M. Hann K. Wheatley R.G. Gray 1998 Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party Br J Haematol 101 130 140
13. M. Chang S.C. Raimondi Y. Ravindranath A.J. Carroll B. Camitta M.V. Gresik 2000 Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821 Leukemia 14 1201 1207
14. G. Levitt 1999 Cardioprotection Br J Haematol 106 860 869
15. G. Hempel D. Reinhardt U. Creutzig J. Boos 2003 Population pharmacokinetics of liposomal daunorubicin in children Br J Clin Pharmacol 56 370 377
16. D. Reinhardt G. Hempel G. Fleischhack A. Schulz J. Boos U. Creutzig 2002 Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children Klin Padiatr 214 188 194
17. B.E. Gibson K. Wheatley I.M. Hann 2005 Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials Leukemia 19 2130 2138
18. A.M. Carella E. Berman M.P. Maraone 1990 Idarubicin in the treatment of acute leukemias.An overview of preclinical and clinical studies Haematologica 75 159 169
19. E. Berman M. McBride 1992 Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells Blood 79 3267 3273
20. J.M. Reid T.W. Pendergrass M.D. Krailo 1990 Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report Cancer Res 50 6525 6528
21. U. Creutzig J. Ritter M. Zimmermann 2001 Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group Leukemia 15 348 354
22. T.A. O'Brien S.J. Russell M.R. Vowels 2002 Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group Blood 100 2708 2716
23. R.O. AU Dillman R.B. Davis M.R. Green R.B. Weiss A.J. Gottlieb S. Caplan 1991 A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B Blood 78 2520 2526
24. D. Tomizawa K. Tabuchi A. Kinoshita R. Hanada H. Kigasawa I. Tsukimoto 2007 Tokyo Children's Cancer Study Group. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group Pediatr Blood Cancer 49 127 132
25. K.R. Crews V. Gandhi D.K. Srivastava B.I. Razzouk X. Tong F.G. Behm 2002 Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia J Clin Oncol 20 4217 4224
26. J. Styczynski M. Wysocki R. Debski E. Juraszewska I. Malinowska E. Stanczak 2002 Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia Leuk Lymphoma 43 1843 1848
27. R.A. Krance C.A. Hurwitz D.R. Head S.C. Raimondi F.G. Behm K.R. Crews 2001 Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases J Clinical Oncology 19 2804 2811
28. J.E. Rubnitz B.I. Razzouk D.K. Srivastava C.H. Pui R.C. Ribeiro V.M. Santana 2004 Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies Leuk Res 28 349 352
29. S.M. Kornblau V. Gandhi H.M. Andreeff M. Beran H.M. Kantarjian C.A. Roller 1996 Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults Leukemia 10 1563 1569
30. P.F. Bross J. Beitz G. Chen X.H. Chen E. Duffy L. Kieffer 2001 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin Cancer Res 7 1490 1496
31. R.J. Arceci J. Sande B. Lange K. Shannon J. Franklin R. Hutchinson 2005 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia Blood 106 1183 1188
32. B. Brethon A. Auvrignon J.M. Cayuela H. Lapillonne G. Leverger A. Baruchel 2006 Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine Haematologica 91 419 421
33. D. Reinhardt S. Diekamp G. Fleischhack C. Corbacioglu H. Jürgens M. Dworzak 2004 Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia Onkologie 27 269 272
34. P. Brown D. Small 2004 FLT3 Inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer Europ JCancer 40 707 721
35. B.D. Smith M. Levis M. Beram F. Giles H. Kantarjian K. Berg 2004 Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical in patients with refractory acute myeloid leukemia Blood 103 3669 3676
36. R.M. Stone D.J. DeAngelo V. Klimek I. Galinsky E. Estey S.D. Nimer 2005 Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood 105 54 60
37. F.J. Giles A.T. Stopeck L.R. Silverman J.E. Lancet M.A. Cooper A.L. Hannah 2003 SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 102 795 801
38. J.E. Lancet I. Gojo J. Gotlib E.J. Feldman J. Greer J.L. Liesveld 2007 A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood 109 1387 1394
39. M. Bleakley L. Lau P.J. Shaw A. Kaufman 2002 Bone marrow transplantation for pediatric AML in first remission: a systematic review and meta-analysis Bone Marrow Transplant 29 843 852
40. R.F. Schlenk K. Dohner J. Krauter S. Frohling A. Corbacioglu L. Bullinger 2008 Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia NEJM 358 1909 1918
41. G. Marcucci M. Radmacher K. Maharry K. Mrozek A. Ruppert P. Paschka 2008 MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia NEJM 358 1919 1928
42. K. Spiekermann R.J. Dirschinger R. Schwab K. Bagrintseva F. Faber C. Buske 2003 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3 Blood 101 1494 1504
43. W. Fiedler H. Serve H. Döhner M. Schwittay O.G. Ottmann A.M. O'Farrell 2005 A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease Blood 105 986 993